IP Library Granted Patent US 10,722,396
Granted Patent B2
US 10,722,396 · App. 16/591,067 · Granted Jul 28, 2020

Apparatus and methods for ocular injection

Inventors: Rafael Victor Andino (Grayson, GA); Vladimir Zarnitsyn (Atlanta, GA); Jesse Yoo (Snellville, GA); Christopher John Brooks (Glen Cove, NY); Trent John Kahute (Atlanta, GA); Justin William Arsenault (Atlanta, GA); David Jackson Trettin (Atlanta, GA); Andrew Kent Bauer (Atlanta, GA); Stephanie Elaine Lewis (Atlanta, GA)
Assignee: CLEARSIDE BIOMEDICAL., INC.
A61F9/0017A61J1/201A61J1/2055A61J1/2096A61M5/2033A61M5/2053A61M5/31A61M5/3293A61M5/34A61M5/344A61M5/346A61M5/347A61M5/348A61M5/349A61M5/46A61M5/482A61M37/0015A61F2250/0007A61F2250/0069A61M2005/31508A61M2037/0023A61M2037/0061A61M2210/0612
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,722,396
App. No.
16/591,067
Granted
Jul 28, 2020
Kind
B2
Abstract

An apparatus includes a housing coupled to a medicament container, which is coupled to a needle. An injection assembly is disposed within the housing and includes an energy storage member and an actuation rod. A distal end portion of the actuation rod is disposed within the medicament container. The energy storage member can produce a force on a proximal end portion of the actuation rod sufficient to move the distal end portion of the actuation rod within the medicament container. This can convey at least a portion of a substance from the medicament container via the needle when a distal tip of the needle is disposed within a first region of a target location. The force is insufficient to move the distal end portion of the actuation rod within the medicament container when the distal tip of the needle is disposed within a second region of the target location.

Claims (42)

1. An apparatus, comprising:

a medicament container, the medicament container including axitinib;

a housing configured to receive a portion of the medicament container;

a hub configured to be coupled to the medicament container and defining a passageway through which a puncture member is disposed, the hub being fixedly coupled to the puncture member such that the hub moves with the puncture member when the puncture member is moved relative to an eye, a distal end surface of the hub being configured to contact a target surface of the eye when the axitinib is conveyed through the puncture member; and

an actuation rod at least partially disposed within the medicament container, the medicament container, the actuation rod, and the puncture member collectively configured such that (1) a portion of the actuation rod moves within the medicament container in response to a force on the actuation rod when a distal end portion of the puncture member is disposed within a suprachoroidal space of the eye, and (2) movement of a distal end portion of the actuation rod within the medicament container in response to the force on the actuation rod is limited when the distal end portion of the puncture member is disposed within a portion of a sclera of the eye, the force having a magnitude less than a threshold value.

2. The apparatus of claim 1 , wherein the threshold value is from about 2N to about 6N.

3. The apparatus of claim 1 , wherein the target surface is any one of a conjunctiva of the eye or the sclera of the eye.

4. The apparatus of claim 1 , wherein the distal end surface of the hub includes a sealing portion configured to define a substantially fluid-tight seal with the target surface when the axitinib is conveyed through the puncture member.

5. The apparatus of claim 4 , wherein the sealing portion is symmetrical about a centerline of the passageway of the hub.

6. The apparatus of claim 1 , wherein a centerline of the puncture member is substantially normal to a surface line tangent to the hub.

7. The apparatus of claim 1 , wherein the force is between about 0.5N and about 2N.

8. The apparatus of claim 1 , wherein the force is applied manually.

9. The apparatus of claim 1 , wherein the hub is configured to be coupled to the medicament container via a threaded coupling.

10. The apparatus of claim 1 , wherein at least a portion of the medicament container is transparent.

11. The apparatus of claim 1 , wherein the distal end surface of the hub is convex.

12. A kit, comprising:

a vial containing axitinib; and

a medical injector, the medical injector including:

a housing, the housing configured to be coupled to a medicament container;

the medicament container, the medicament container configured to receive the axitinib from the vial;

a hub, the hub configured to be coupled to the medicament container and defining a passageway through which a puncture member is disposed, the puncture member being fixedly coupled to the hub, at least a portion of a distal end surface of the hub having (1) a hemispherical shape, and (2) a sealing portion configured to define a substantially fluid-tight seal with a target surface of an eye when the axitinib is conveyed through the puncture member; and

an actuation rod, the actuation rod configured to be at least partially disposed within the medicament container,

the medicament container, the actuation rod, and the puncture member collectively configured such that (1) a portion of the actuation rod moves within the medicament container in response to a force on the actuation rod when a distal end portion of the puncture member is disposed within a suprachoroidal space of the eye, and (2) movement of a distal end portion of the actuation rod within the medicament container in response to the force on the actuation rod is limited when the distal end portion of the puncture member is disposed within a portion of a sclera of the eye, the force having a magnitude less than a threshold value.

13. The kit of claim 12 , wherein the threshold value is from about 2N to about 6N.

14. The kit of claim 12 , wherein the target surface is any one of a conjunctiva of the eye or the sclera of the eye.

15. The kit of claim 12 , wherein the sealing portion is symmetrical about a centerline of the passageway of the hub.

16. The kit of claim 12 , wherein a centerline of the puncture member is substantially normal to a surface line tangent to the hub.

17. The kit of claim 12 , wherein the force is between about 0.5N and about 2N.

18. The kit of claim 12 , wherein the force is applied manually.

19. The kit of claim 12 , wherein the hemispherical shape is convex.

20. The kit of claim 12 , wherein the hub is configured to be coupled to the medicament container via a threaded coupling.

21. The kit of claim 12 , wherein at least a portion of the medicament container is transparent.

22. An apparatus, comprising:

a medicament container configured to contain axitinib;

a housing configured to receive a portion of the medicament container;

a hub configured to be coupled to the medicament container and defining a passageway through which a puncture member is disposed, the hub being fixedly coupled to the puncture member such that the hub moves with the puncture member when the puncture member is moved relative to an eye, at least a portion of a distal end surface of the hub having a convex shape, the hub being configured to contact a target surface of the eye when the axitinib is conveyed through the puncture member; and

an actuation rod at least partially disposed within the medicament container, the medicament container, the actuation rod, and the puncture member collectively configured such that (1) a portion of the actuation rod moves within the medicament container in response to a force on the actuation rod when a distal end portion of the puncture member is disposed within a suprachoroidal space of the eye, and (2) movement of a distal end portion of the actuation rod within the medicament container in response to the force on the actuation rod is limited when the distal end portion of the puncture member is disposed within a portion of a sclera of the eye, the force having a magnitude less than a threshold value.

23. The apparatus of claim 22 , wherein the threshold value is from about 2N to about 6N.

24. The apparatus of claim 22 , wherein a centerline of the puncture member is substantially normal to a surface line tangent to the hub.

25. The apparatus of claim 22 , wherein the force is between about 0.5N and about 2N.

26. The apparatus of claim 22 , wherein the force is applied manually.

27. The apparatus of claim 22 , wherein the portion of the sclera is an upper portion of the sclera.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: ANDINO, RAFAEL VICTOR; ZARNITSYN, VLADIMIR
To: CLEARSIDE BIOMEDICAL, INC.
Reel/Frame 051235/0067 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: KAHUTE, TRENT JOHN; ARSENAULT, JUSTIN WILLIAM; TRETTIN, DAVID JACKSON; BAUER, ANDREW KENT; LEWIS, STEPHANIE ELAINE
To: THRIVE CONSULTING, LLC
Reel/Frame 051235/0112 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: YOO, JESSE
To: CLEARSIDE BIOMEDICAL, INC.
Reel/Frame 051235/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: THRIVE CONSULTING, LLC
To: CLEARSIDE BIOMEDICAL, INC.
Reel/Frame 051235/0171 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: BROOKS, CHRISTOPHER JOHN
To: HABITECH DESIGN & DEVELOPMENT WORKS LLC
Reel/Frame 051235/0183 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: HABITECH DESIGN & DEVELOPMENT WORKS LLC
To: CLEARSIDE BIOMEDICAL, INC.
Reel/Frame 051235/0200 →
Cited By (7)
US 1,106,444 US 1,116,103 US 1,120,314 US 12,201,558 US 12,274,865 US 12,649,031 US 12,691,227